KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TherapeuticsMD (TXMD) Accumulated Expenses (2016 - 2025)

TherapeuticsMD's Accumulated Expenses history spans 14 years, with the latest figure at $1.7 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 18.15% year-over-year to $1.7 million; the TTM value through Dec 2025 reached $1.7 million, down 18.15%, while the annual FY2025 figure was $1.7 million, 18.15% down from the prior year.
  • Accumulated Expenses reached $1.7 million in Q4 2025 per TXMD's latest filing, up from $256000.0 in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $46.0 million in Q1 2021 to a low of $129000.0 in Q1 2025.
  • Average Accumulated Expenses over 4 years is $6.9 million, with a median of $2.1 million recorded in 2021.
  • The largest YoY upside for Accumulated Expenses was 655.24% in 2021 against a maximum downside of 94.77% in 2021.
  • A 4-year view of Accumulated Expenses shows it stood at $2.0 million in 2021, then soared by 57.04% to $3.1 million in 2023, then crashed by 32.11% to $2.1 million in 2024, then fell by 18.15% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for TXMD's Accumulated Expenses are $1.7 million (Q4 2025), $256000.0 (Q3 2025), and $200000.0 (Q2 2025).